Epoetin Beta in Treating Fatigue and Anemia in Patients Receiving Palliative Care for Malignant Solid Tumors
RATIONALE: Epoetin beta may cause the body to make more red blood cells and may help relieve fatigue in patients with malignant solid tumors receiving palliative care.
PURPOSE: This phase II trial is studying how well epoetin beta works in treating fatigue and anemia in patients receiving palliative care for malignant solid tumors.
|Anemia Fatigue Unspecified Adult Solid Tumor, Protocol Specific||Biological: epoetin beta Procedure: quality-of-life assessment||Phase 2|
|Study Design:||Allocation: Non-Randomized
Primary Purpose: Supportive Care
|Official Title:||Phase 2 Study Evaluating the Efficacy of Epoetin Beta (Neocormon®) For Fatigue and Quality of Life of Patients Receiving Palliative Care for a Solid Malignant Tumor|
- Quality of life
- Hemoglobin level
|Study Start Date:||November 2005|
|Primary Completion Date:||May 2011 (Final data collection date for primary outcome measure)|
- Evaluate the impact of epoetin beta on fatigue and quality of life of patients receiving palliative care for malignant solid tumors.
- Evaluate the impact of epoetin beta on hemoglobin level (increase > 2 g/dL).
OUTLINE: Patients receive epoetin beta subcutaneously once a week for up to 3 months.
Fatigue, quality of life, and hemoglobin and reticulocyte levels are assessed every 4 weeks.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00559195
|Centre Hospital Regional Universitaire de Limoges|
|Limoges, France, 87042|
|Study Chair:||Jean-Luc Labourey||Centre Hospital Regional Universitaire de Limoges|